Idera Pharmaceuticals is a biopharmaceutical company. The company's focus is on its Toll-like receptor, or TLR, agonist, tilsotolimod (IMO-2125), for oncology. The company's TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The company is developing tilsotolimod, via intratumoral injection, for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab, an anti-CTLA4 antibody marketed as Yervoy? by Bristol-Myers Squibb Company (BMS). The company is also evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-PD1 antibody marketed as Opdivo? by BMS, and ipilimumab for the treatment of multiple solid tumors in a Phase 2 trial.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States